NYCKidSeq项目:将基因组学纳入纽约市多元儿童临床照护的随机对照试验研究方案
NYCKidSeq是一项随机对照试验,计划招募1130名主要来自哈莱姆和布朗克斯区、疑似患有神经、心血管或免疫系统遗传病的儿童及年轻成人。研究将为每名参与者进行全基因组测序(先证者、 duo或trio)和靶向基因panel检测,评估两种检测模式的临床效用、成本和诊断率,并测试数字平台GUÍA和GenomeDiver工具的效果。
要点
- 招募1130名疑似遗传病儿童,覆盖神经、心血管和免疫三类疾病。
- 每名参与者同时接受全基因组测序和靶向基因panel检测,比较诊断率与成本。
- 评估GUÍA数字平台改善英语和西班牙语家庭对基因组结果的理解。
核心结论
- 该研究旨在为在服务多元人群的卫生系统中实施基因组医学提供策略,方法需具备临床实用性、技术先进性、文化敏感性和伦理合理性。
研究设计与样本
- 随机对照试验,计划招募1130名主要来自哈莱姆和布朗克斯区的儿童及年轻成人,疑似患有神经、心血管或免疫系统遗传病。
- 每名参与者进行两种临床基因检测:全基因组测序(先证者、duo或trio,取决于样本可及性)和先证者靶向基因panel。
- 在基线(0个月)、结果披露访视(ROR1,+3个月)和随访访视(ROR2,+9个月)三个研究访视点收集调查数据。
- 开展预试验评估数字工具GenomeDiver,旨在增强临床医生与基因检测实验室之间的沟通。
关键数值与推荐
- 评估两种检测模式的临床效用、成本和诊断率。
- 评估GUÍA数字平台对英语和西班牙语家庭基因组结果返还体验的数字化和参与者理解改善情况。
- 结局评估父母对接收孩子基因组结果的理解和态度,以及结果的行为、心理和社会影响。
- 评估GenomeDiver与标准实践相比提高诊断率、改善临床医生进行靶向反向表型分析的能力以及提高基因检测实验室人员效率的能力。
临床怎么用
- 通过数字平台GUÍA数字化基因组结果返还体验,可能改善多元语言家庭对结果的理解。
- GenomeDiver工具可能增强临床医生与检测实验室的沟通,提高诊断率和反向表型分析效率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increasingly, genomics is informing clinical practice, but challenges remain for medical professionals lacking genetics expertise, and in access to and clinical utility of genomic testing for minority and underrepresented populations. The latter is a particularly pernicious problem due to the historical lack of inclusion of racially and ethnically diverse populations in genomic research and genomic medicine. A further challenge is the rapidly changing landscape of genetic tests and considerations of cost, interpretation, and diagnostic yield for emerging modalities like whole-genome sequencing. METHODS: The NYCKidSeq project is a randomized controlled trial recruiting 1130 children and young adults predominantly from Harlem and the Bronx with suspected genetic disorders in three disease categories: neurologic, cardiovascular, and immunologic. Two clinical genetic tests will be performed for each participant, either proband, duo, or trio whole-genome sequencing (depending on sample availability) and proband targeted gene panels. Clinical utility, cost, and diagnostic yield of both testing modalities will be assessed. This study will evaluate the use of a novel, digital platform (GUÍA) to digitize the return of genomic results experience and improve participant understanding for English- and Spanish-speaking families. Surveys will collect data at three study visits: baseline (0 months), result disclosure visit (ROR1, + 3 months), and follow-up visit (ROR2, + 9 months). Outcomes will assess parental understanding of and attitudes toward receiving genomic results for their child and behavioral, psychological, and social impact of results. We will also conduct a pilot study to assess a digital tool called GenomeDiver designed to enhance communication between clinicians and genetic testing labs. We will evaluate GenomeDiver's ability to increase the diagnostic yield compared to standard practices, improve clinician's ability to perform targeted reverse phenotyping, and increase the efficiency of genetic testing lab personnel. DISCUSSION: The NYCKidSeq project will contribute to the innovations and best practices in communicating genomic test results to diverse populations. This work will inform strategies for implementing genomic medicine in health systems serving diverse populations using methods that are clinically useful, technologically savvy, culturally sensitive, and ethically sound. TRIAL REGISTRATION: ClinicalTrials.gov NCT03738098 . Registered on November 13, 2018 Trial Sponsor: Icahn School of Medicine at Mount Sinai Contact Name: Eimear Kenny, PhD (Principal Investigator) Address: Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Pl., Box 1003, New York, NY 10029 Email: eimear.kenny@mssm.edu.
引用
- Odgis JA, Gallagher KM, Suckiel SA, et al. The NYCKidSeq project: study protocol for a randomized controlled trial incorporating genomics into the clinical care of diverse New York City children. Trials. 2021. PMID: 33446240. doi:10.1186/s13063-020-04953-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。